Rare Cancers Bill Debate
Full Debate: Read Full DebateJohn Slinger
Main Page: John Slinger (Labour - Rugby)Department Debates - View all John Slinger's debates with the Department of Health and Social Care
(1 day, 19 hours ago)
Commons ChamberI commend my hon. Friend the Member for Edinburgh South West (Dr Arthur) on bringing forward his important Bill. I also commend hon. Members across this House for their powerful and moving speeches, particularly those of my hon. Friends the Members for Calder Valley (Josh Fenton-Glynn), for Mitcham and Morden (Dame Siobhain McDonagh) and for Cumbernauld and Kirkintilloch (Katrina Murray), who showed that the love for a sibling or child persists forever and can be harnessed to bring about change.
I am speaking today because my constituent Mr Peter Realf contacted me about his son Stephen, who was training to be an RAF pilot when he was diagnosed with astrocytoma. He was just 19. Tragically, despite his cancer being described as “low-grade” and despite receiving treatment that prolonged his life, he died six years later, aged just 26. I cannot imagine the pain and sense of loss felt by Stephen’s family and friends, and my heart goes out to them and all those who have faced the consequences of this cruel disease.
Mr Realf and his family have campaigned tirelessly since Stephen’s death to address the baffling paradox that despite brain tumours killing more children and adults under 40 than any other cancer, and despite them robbing patients of more years of their life than any other cancer, only a fraction of the Government’s research funding into cancer is used for brain tumours at just 1.37% of national spend, according to the charity Brain Tumour Research.
Stephen Realf’s case is stark: a talented, hard-working and clearly impressive young man who died young, losing perhaps 50 years of life and 50 years of potential. A huge public petition and an article written by Stephen’s sister Maria led in 2015 to the then-new Petitions Committee of this House conducting its first inquiry. I challenge any right hon. and hon. Member to read the report’s conclusions from 2016—nine years ago—and not to conclude that, in general, little has improved since then.
We should be deeply concerned—though perhaps, as my hon. Friend the Member for Mitcham and Morden has indicated, the appropriate emotion is a stronger one. We hear of the additional £40 million pledged by the last Government and how, according to reports, £28 million of it is yet to be released to scientists. After one of the relevant authorities, the National Institute for Health and Care Research, came to see us at the all-party parliamentary group on brain tumours recently, my colleagues and the campaigners, patients and families present still could not fathom just why the money had not been spent in all those years.
I am relatively new to this place, but I have been observing politics for a long time, and something about this issue does not fit. It does not feel right. Something is profoundly wrong. Where there should be outrage, there appears to be relative indifference—not to death and suffering, of course, but to the need for radical changes to get money flowing. Where there should be urgency among the authorities—for, after all, people are dying, often young—there appears to be a degree of inertia, and where there should be action, we often get lost in the chilling snowstorm of bureaucracy.
I am not impugning the decency, compassion or professionalism of officials, researchers or clinicians; they are of course committed to helping to cure, treat and prevent cancer. However, as with other examples of institutional failure, it does not take overt malice, just the absence of grip and tenacity in the face of injustice, or of challenging the status quo, for good things not to happen, or even for bad and preventable outcomes to occur.
I do not know why progress does not seem to be happening. What reasons could there possibly be for the continuing paradox of the underfunding of rare cancer research? We must find out the reasons and overcome those forces, or perhaps even vested interests, because the stakes could not be higher. Little has changed in terms of treatment and survivability since the 1960s. Patients with brain tumours do not have time on their side, as many hon. Members have said; sadly, most of those diagnosed die within five years.
The following statistics from Brain Tumour Research are stark, but, before I read them, I should say that I am glad of the progress on more common cancers, which have affected my family as they have every family. Brain Tumour Research states:
“Brain tumours kill more children than leukaemia. Brain tumours kill more men under 70 than prostate cancer and more women under 35 than breast cancer. Incidences of and deaths from brain tumours are increasing… At the current rate of spending, it could take 100 years for brain cancer to catch up with developments in other diseases and find a cure.”
That is why the Bill introduced by my hon. Friend the Member for Edinburgh South West is so needed. It offers practical steps to get more funding into research to take on and defeat those cancers.
Finally, I know my ministerial colleagues want only the best for patients, so I gently encourage them, if they have not already done so, to ask this question of officials: “Why is it that research into these cancers, which cause so much death and suffering among the young and rob so many people of so many years of life, are receiving so little funding?” Ministers should keep asking until they get a satisfactory answer. MPs should keep asking until we get a satisfactory answer. We should work together, cross-party if possible, to overcome obstacles and we should certainly pass this Bill. The pain, loss, concern and even anger must be channelled into urgent, substantive action. We owe it to the past, current and future victims of rare cancers and to their families.